Pharmacology Quiz: Hiv Antiretroviral Therapy
20 questions · exam conditions
0:00
Hiv Antiretroviral TherapyQuestion 1 of 20

The fusion inhibitor enfuvirtide must be administered via subcutaneous injection twice daily. This demanding route of administration is a direct consequence of the drug's fundamental chemical nature, which is that of a:

small molecule heterocyclic compound that is subject to extensive first-pass metabolism.
large synthetic peptide that would be rapidly degraded by proteases in the gastrointestinal tract.
pro-drug that requires enzymatic activation in the subcutaneous tissue before systemic absorption.
highly charged nucleotide analog that is too polar to be absorbed across the intestinal lumen.
← Back to quizzes

Pharmacology Quiz

Pharmacology Quiz: Hiv Antiretroviral Therapy

Practice Hiv Antiretroviral Therapy in Pharmacology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Hiv Antiretroviral Therapy, giving you a quick way to practice the rules, question types, and explanations that matter most for Pharmacology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

The fusion inhibitor enfuvirtide must be administered via subcutaneous injection twice daily. This demanding route of administration is a direct consequence of the drug's fundamental chemical nature, which is that of a:

  1. small molecule heterocyclic compound that is subject to extensive first-pass metabolism.
  2. large synthetic peptide that would be rapidly degraded by proteases in the gastrointestinal tract. (correct answer)
  3. pro-drug that requires enzymatic activation in the subcutaneous tissue before systemic absorption.
  4. highly charged nucleotide analog that is too polar to be absorbed across the intestinal lumen.
Explanation: The correct answer is B. Enfuvirtide is a 36-amino-acid synthetic peptide that mimics a segment of the HIV gp41 protein. As a peptide, if taken orally, it would be digested by proteases in the stomach and small intestine and not absorbed intact. Therefore, it must be administered parenterally, via subcutaneous injection. A describes many oral drugs, but not a peptide. C is incorrect; it is not a pro-drug requiring local activation. D describes properties of some NRTIs, but enfuvirtide is not a nucleotide analog.

Question 2

A patient's HIV genotype report reveals the M184V mutation in reverse transcriptase, conferring high-level resistance to lamivudine. Paradoxically, the presence of the M184V mutation is known to increase the in-vitro susceptibility of the virus to which of the following antiretroviral agents?

  1. Efavirenz
  2. Atazanavir
  3. Dolutegravir
  4. Tenofovir (correct answer)
Explanation: When you encounter HIV drug resistance questions, focus on how mutations can create unexpected drug interactions and cross-resistance patterns. The M184V mutation is particularly important because while it causes high-level resistance to certain drugs, it can paradoxically enhance sensitivity to others. The M184V mutation in HIV reverse transcriptase creates a fascinating pharmacological phenomenon. This mutation substitutes valine for methionine at position 184, which not only confers resistance to lamivudine and emtricitabine but also reduces the enzyme's processivity and fidelity. This reduction in viral fitness creates hypersusceptibility to tenofovir (D). The M184V mutation appears to impair the virus's ability to discriminate against tenofovir, making it more likely to incorporate this nucleotide analog, thereby increasing the drug's antiviral efficacy. Efavirenz (A) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works at a different binding site than nucleoside analogs, so M184V doesn't create hypersusceptibility to it. Atazanavir (B) is a protease inhibitor that targets a completely different enzyme, making it unaffected by reverse transcriptase mutations. Dolutegravir (C) is an integrase inhibitor that acts on yet another viral enzyme, so reverse transcriptase mutations don't influence its activity. Remember this key principle: the M184V mutation creates a "fitness cost" that can be exploited therapeutically. When studying HIV pharmacology, pay special attention to how resistance mutations can sometimes create vulnerabilities to other drugs in the same class—this concept appears frequently on pharmacology exams and is clinically relevant for treatment planning.

Question 3

Both nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) target the same viral enzyme. Which statement accurately describes a fundamental difference in their mechanism of action?

  1. NRTIs act as chain terminators after being incorporated into the growing viral DNA strand, while NNRTIs are not incorporated. (correct answer)
  2. NNRTIs must be tri-phosphorylated by host cell kinases to become active, whereas NRTIs are directly active upon entering the cell.
  3. NRTIs bind to a distant allosteric site on reverse transcriptase to induce a conformational change, while NNRTIs bind to the active catalytic site.
  4. NRTIs are primarily effective against HIV-1, while NNRTIs demonstrate broad activity against both HIV-1 and HIV-2.
Explanation: The correct answer is A. The key mechanistic difference is that NRTIs are nucleoside/tide analogs that, after phosphorylation, are incorporated by reverse transcriptase into the proviral DNA. Because they lack a 3'-hydroxyl group, they terminate DNA chain elongation. NNRTIs, in contrast, are not incorporated into the DNA; they bind to an allosteric (non-catalytic) site on the enzyme, inducing a conformational change that inactivates it. B and C have the mechanisms reversed. D is incorrect; NNRTIs are generally not active against HIV-2, whereas most NRTIs are.

Question 4

A pregnant patient with HIV is being managed to prevent perinatal transmission. Historically, zidovudine (AZT), an NRTI, was a key component of therapy. What is the specific molecular mechanism by which activated zidovudine suppresses HIV replication?

  1. It allosterically inhibits the RNA-dependent DNA polymerase activity of reverse transcriptase.
  2. It chelates divalent metal ions in the active site of the integrase enzyme, blocking DNA strand transfer.
  3. It prevents the cleavage of Gag-Pol polyproteins, resulting in immature, non-infectious virions.
  4. It competitively inhibits the incorporation of thymidine triphosphate during viral DNA synthesis. (correct answer)
Explanation: When you encounter questions about nucleoside reverse transcriptase inhibitors (NRTIs) like zidovudine, focus on their mechanism as DNA chain terminators that mimic natural nucleosides. Zidovudine works by mimicking thymidine, one of the four natural DNA building blocks. Once phosphorylated to its triphosphate form inside the cell, zidovudine triphosphate competes directly with natural thymidine triphosphate for incorporation into the growing viral DNA chain during reverse transcription. However, zidovudine lacks a 3'-hydroxyl group, so when it's incorporated, DNA synthesis terminates because no further nucleotides can be added. This competitive inhibition effectively blocks HIV replication at the reverse transcription step. Choice A describes non-nucleoside reverse transcriptase inhibitors (NNRTIs) like efavirenz, which bind to an allosteric site and change the enzyme's shape rather than competing for the active site. Choice B incorrectly describes integrase strand transfer inhibitors like raltegravir, which target a completely different step in the HIV life cycle. Choice C describes protease inhibitors, which prevent proper viral protein processing rather than affecting DNA synthesis. The correct answer is D because zidovudine triphosphate directly competes with thymidine triphosphate during viral DNA synthesis, leading to chain termination. Study tip: Remember that NRTIs are "fake building blocks" - they compete with natural nucleotides (competitive inhibition) and terminate DNA chains, while NNRTIs work through allosteric inhibition. This distinction frequently appears on pharmacology exams when testing antiretroviral mechanisms.

Question 5

A patient newly diagnosed with HIV is initiated on monotherapy with lamivudine. Within a few months, virologic failure is observed, characterized by a rapid rebound in plasma HIV RNA. What is the most likely molecular explanation for this treatment failure?

  1. The M184V mutation in the reverse transcriptase gene developed, conferring high-level resistance to lamivudine. (correct answer)
  2. The virus upregulated P-glycoprotein efflux pumps in host CD4+ cells, preventing intracellular drug accumulation.
  3. Lamivudine was rapidly inactivated by host cell cytochrome P450 enzymes before it could be phosphorylated.
  4. The patient's HIV strain developed resistance due to a key mutation in the active site of the protease enzyme.
Explanation: The correct answer is A. HIV monotherapy fails due to the rapid selection of drug-resistant viral variants. For lamivudine (and emtricitabine), the M184V mutation in reverse transcriptase is a single point mutation that can be selected quickly and confers high-level resistance, making it a classic example of why combination therapy is essential. B is incorrect because while P-glycoprotein efflux is a mechanism of drug resistance in some contexts (e.g., oncology), it is not the primary mechanism for HIV resistance to NRTIs. C is incorrect as NRTIs like lamivudine are not major substrates for CYP450 enzymes. D is incorrect because a mutation in the protease enzyme would confer resistance to protease inhibitors, not to an NRTI like lamivudine, which targets reverse transcriptase.

Question 6

The primary goal of modern antiretroviral therapy (ART) is to achieve and maintain a plasma HIV RNA level below the limit of detection. According to major public health findings, what is the most significant clinical and social consequence of a patient achieving and maintaining this state?

  1. Complete eradication of the latent HIV reservoir in resting memory CD4+ T-cells.
  2. Full restoration of all immune functions and inflammatory markers to pre-infection levels.
  3. The risk of transmitting HIV to sexual partners is reduced to effectively zero. (correct answer)
  4. Elimination of the elevated risk for non-AIDS comorbidities, such as cardiovascular disease.
Explanation: The correct answer is C. Large clinical trials have demonstrated that when a person with HIV achieves and maintains an undetectable viral load through ART, they do not sexually transmit the virus to others. This concept is known as 'Undetectable = Untransmittable' (U=U). It is a profound consequence of effective ART, with major implications for public health, prevention, and reducing stigma. A is incorrect; ART suppresses replication but does not eradicate the latent reservoir, which is why it is not a cure. B is incorrect; while immune function (CD4 count) improves dramatically, some immune dysregulation and inflammation may persist. D is incorrect; ART reduces the risk of non-AIDS comorbidities but does not eliminate it entirely.

Question 7

A patient on an older ART regimen containing stavudine (d4T) develops painful peripheral neuropathy and pancreatitis. These dose-limiting toxicities are primarily attributed to the drug's off-target inhibition of which essential host cell enzyme?

  1. Cytochrome P450 3A4
  2. Cellular topoisomerase I
  3. Host cell RNA polymerase II
  4. Mitochondrial DNA polymerase gamma (correct answer)
Explanation: When you encounter questions about nucleoside reverse transcriptase inhibitors (NRTIs) like stavudine causing peripheral neuropathy and pancreatitis, think about mitochondrial toxicity. These symptoms are classic signs of mitochondrial dysfunction, which helps point you toward the mechanism. Stavudine's dose-limiting toxicities stem from its off-target inhibition of mitochondrial DNA polymerase gamma (pol γ). This enzyme is responsible for replicating mitochondrial DNA, which is essential for cellular energy production. When stavudine inhibits pol γ, it disrupts mitochondrial DNA synthesis, leading to mitochondrial dysfunction. Tissues with high energy demands—like peripheral nerves and pancreatic cells—are particularly vulnerable, explaining why patients develop painful neuropathy and pancreatitis. Answer choice A (Cytochrome P450 3A4) is incorrect because this hepatic enzyme metabolizes drugs but doesn't cause the specific mitochondrial toxicities described. Choice B (Cellular topoisomerase I) is wrong—this nuclear enzyme relieves DNA supercoiling during replication but isn't the target causing these particular side effects. Choice C (Host cell RNA polymerase II) is also incorrect since this enzyme transcribes mRNA in the nucleus and wouldn't produce mitochondrial dysfunction symptoms. The correct answer is D because mitochondrial DNA polymerase gamma inhibition directly explains both the mechanism and the clinical presentation. Study tip: Remember that older NRTIs (stavudine, didanosine, zidovudine) commonly cause mitochondrial toxicity through pol γ inhibition. When you see peripheral neuropathy, pancreatitis, or lactic acidosis with these drugs, think mitochondrial DNA polymerase gamma—it's a high-yield association for pharmacology exams.

Question 8

A patient newly diagnosed with HIV is initiated on monotherapy with lamivudine. Within a few months, virologic failure is observed, characterized by a rapid rebound in plasma HIV RNA. What is the most likely molecular explanation for this treatment failure?

  1. The M184V mutation in the reverse transcriptase gene developed, conferring high-level resistance to lamivudine. (correct answer)
  2. The virus upregulated P-glycoprotein efflux pumps in host CD4+ cells, preventing intracellular drug accumulation.
  3. Lamivudine was rapidly inactivated by host cell cytochrome P450 enzymes before it could be phosphorylated.
  4. The patient's HIV strain developed resistance due to a key mutation in the active site of the protease enzyme.
Explanation: The correct answer is A. HIV monotherapy fails due to the rapid selection of drug-resistant viral variants. For lamivudine (and emtricitabine), the M184V mutation in reverse transcriptase is a single point mutation that can be selected quickly and confers high-level resistance, making it a classic example of why combination therapy is essential. B is incorrect because while P-glycoprotein efflux is a mechanism of drug resistance in some contexts (e.g., oncology), it is not the primary mechanism for HIV resistance to NRTIs. C is incorrect as NRTIs like lamivudine are not major substrates for CYP450 enzymes. D is incorrect because a mutation in the protease enzyme would confer resistance to protease inhibitors, not to an NRTI like lamivudine, which targets reverse transcriptase.

Question 9

A clinician is choosing between an NNRTI-based regimen and an INSTI-based regimen for a treatment-naive patient with a complex medication history. Which of the following represents a key pharmacological distinction that favors the selection of a modern INSTI-based regimen in this scenario?

  1. NNRTIs possess a significantly higher genetic barrier to resistance, making them more forgiving of occasional missed doses.
  2. INSTIs generally have a more favorable profile regarding drug-drug interactions mediated by the cytochrome P450 system. (correct answer)
  3. NNRTIs do not require intracellular phosphorylation for activation, leading to a more rapid onset of antiviral activity.
  4. INSTIs primarily act by preventing the initial binding and entry of HIV into the host CD4+ cell.
Explanation: The correct answer is B. Modern integrase strand transfer inhibitors (INSTIs) like bictegravir and dolutegravir generally have fewer and less severe drug-drug interactions compared to older NNRTIs (e.g., efavirenz) and protease inhibitors, which are notorious for their complex interactions as substrates, inhibitors, or inducers of CYP450 enzymes. This makes INSTIs a preferred choice in patients on multiple medications. A is incorrect; NNRTIs (especially first-generation ones) have a low genetic barrier to resistance. C is a true statement about NNRTIs but not the primary clinical reason to prefer an INSTI, as both classes have rapid antiviral effects. D is incorrect; this describes the mechanism of entry inhibitors, not INSTIs, which block the integration of viral DNA into the host genome.

Question 10

A patient on a long-term ART regimen presents with bilateral dorsocervical fat pad enlargement ('buffalo hump'), central fat accumulation, hyperlipidemia, and new-onset insulin resistance. Which antiretroviral class, particularly its older agents, is most strongly associated with this constellation of metabolic complications?

  1. Integrase strand transfer inhibitors (INSTIs)
  2. Protease inhibitors (PIs) (correct answer)
  3. Nucleoside reverse transcriptase inhibitors (NRTIs)
  4. CCR5 antagonists
Explanation: The correct answer is B. The clinical picture described is characteristic of HIV-associated lipodystrophy syndrome, which includes both lipohypertrophy (fat accumulation) and metabolic disturbances like dyslipidemia and insulin resistance. This syndrome is most classically associated with older protease inhibitors (e.g., indinavir, nelfinavir). While INSTIs (A) can be associated with weight gain, it is typically not in the classic lipodystrophic pattern. Older NRTIs (C) are associated with the opposite effect, lipoatrophy (fat loss), particularly in the face and limbs. CCR5 antagonists (D) are not strongly linked to this specific metabolic syndrome.

Question 11

A patient with multi-drug resistant HIV is being considered for treatment with the CCR5 antagonist maraviroc. Which of the following evaluations is an essential prerequisite before this specific agent can be initiated?

  1. An HLA-B*5701 screening test to assess for hypersensitivity risk.
  2. A viral tropism assay to determine if the virus utilizes the CCR5 co-receptor for cell entry. (correct answer)
  3. A genotype resistance test for mutations in the viral integrase gene.
  4. Measurement of baseline serum creatinine and calculation of creatinine clearance.
Explanation: The correct answer is B. Maraviroc is a CCR5 antagonist, meaning it blocks the CCR5 co-receptor on the surface of CD4+ cells, which some strains of HIV use to enter the cell. However, other HIV strains use a different co-receptor, CXCR4 (X4-tropic), or both (dual/mixed-tropic). Maraviroc is only effective against CCR5-tropic virus. Therefore, a tropism test is mandatory before starting therapy to ensure the patient's virus is susceptible. A is the prerequisite test for abacavir. C would be relevant for starting an INSTI. D is important for dose-adjusting many drugs, but it is not the specific, essential prerequisite for maraviroc's mechanism of action.

Question 12

The fusion inhibitor enfuvirtide must be administered via subcutaneous injection twice daily. This demanding route of administration is a direct consequence of the drug's fundamental chemical nature, which is that of a:

  1. small molecule heterocyclic compound that is subject to extensive first-pass metabolism.
  2. large synthetic peptide that would be rapidly degraded by proteases in the gastrointestinal tract. (correct answer)
  3. pro-drug that requires enzymatic activation in the subcutaneous tissue before systemic absorption.
  4. highly charged nucleotide analog that is too polar to be absorbed across the intestinal lumen.
Explanation: The correct answer is B. Enfuvirtide is a 36-amino-acid synthetic peptide that mimics a segment of the HIV gp41 protein. As a peptide, if taken orally, it would be digested by proteases in the stomach and small intestine and not absorbed intact. Therefore, it must be administered parenterally, via subcutaneous injection. A describes many oral drugs, but not a peptide. C is incorrect; it is not a pro-drug requiring local activation. D describes properties of some NRTIs, but enfuvirtide is not a nucleotide analog.

Question 13

The antiretroviral activity of tenofovir disoproxil fumarate (TDF) is dependent on a series of intracellular events. Which sequence correctly represents the steps required for TDF to inhibit HIV replication?

  1. Hydrolysis to tenofovir -> Phosphorylation to tenofovir diphosphate -> Incorporation into viral RNA.
  2. Phosphorylation to TDF triphosphate -> Competitive inhibition of viral protease -> Premature chain termination.
  3. Hydrolysis to tenofovir -> Phosphorylation to tenofovir diphosphate -> Competitive inhibition of reverse transcriptase. (correct answer)
  4. Direct binding to an allosteric site on reverse transcriptase -> Conformational change -> Non-competitive inhibition.
Explanation: The correct answer is C. TDF is a pro-drug. First, esterases in the plasma and cells hydrolyze it to its active form, tenofovir. Tenofovir is a nucleotide analog, so it is then phosphorylated twice by host cell kinases to become tenofovir diphosphate. This active metabolite competes with the natural substrate (deoxyadenosine triphosphate) for incorporation by reverse transcriptase into the growing viral DNA, causing chain termination. A is incorrect because it is incorporated into DNA, not RNA. B is incorrect because TDF is an NRTI, not a PI, and the prodrug itself is not phosphorylated. D describes the mechanism of an NNRTI.

Question 14

A pregnant patient with HIV is being managed to prevent perinatal transmission. Historically, zidovudine (AZT), an NRTI, was a key component of therapy. What is the specific molecular mechanism by which activated zidovudine suppresses HIV replication?

  1. It allosterically inhibits the RNA-dependent DNA polymerase activity of reverse transcriptase.
  2. It chelates divalent metal ions in the active site of the integrase enzyme, blocking DNA strand transfer.
  3. It prevents the cleavage of Gag-Pol polyproteins, resulting in immature, non-infectious virions.
  4. It competitively inhibits the incorporation of thymidine triphosphate during viral DNA synthesis. (correct answer)
Explanation: When you encounter questions about nucleoside reverse transcriptase inhibitors (NRTIs) like zidovudine, focus on their mechanism as DNA chain terminators that mimic natural nucleosides. Zidovudine works by mimicking thymidine, one of the four natural DNA building blocks. Once phosphorylated to its triphosphate form inside the cell, zidovudine triphosphate competes directly with natural thymidine triphosphate for incorporation into the growing viral DNA chain during reverse transcription. However, zidovudine lacks a 3'-hydroxyl group, so when it's incorporated, DNA synthesis terminates because no further nucleotides can be added. This competitive inhibition effectively blocks HIV replication at the reverse transcription step. Choice A describes non-nucleoside reverse transcriptase inhibitors (NNRTIs) like efavirenz, which bind to an allosteric site and change the enzyme's shape rather than competing for the active site. Choice B incorrectly describes integrase strand transfer inhibitors like raltegravir, which target a completely different step in the HIV life cycle. Choice C describes protease inhibitors, which prevent proper viral protein processing rather than affecting DNA synthesis. The correct answer is D because zidovudine triphosphate directly competes with thymidine triphosphate during viral DNA synthesis, leading to chain termination. Study tip: Remember that NRTIs are "fake building blocks" - they compete with natural nucleotides (competitive inhibition) and terminate DNA chains, while NNRTIs work through allosteric inhibition. This distinction frequently appears on pharmacology exams when testing antiretroviral mechanisms.

Question 15

A patient with multi-drug resistant HIV is being considered for treatment with the CCR5 antagonist maraviroc. Which of the following evaluations is an essential prerequisite before this specific agent can be initiated?

  1. An HLA-B*5701 screening test to assess for hypersensitivity risk.
  2. A viral tropism assay to determine if the virus utilizes the CCR5 co-receptor for cell entry. (correct answer)
  3. A genotype resistance test for mutations in the viral integrase gene.
  4. Measurement of baseline serum creatinine and calculation of creatinine clearance.
Explanation: The correct answer is B. Maraviroc is a CCR5 antagonist, meaning it blocks the CCR5 co-receptor on the surface of CD4+ cells, which some strains of HIV use to enter the cell. However, other HIV strains use a different co-receptor, CXCR4 (X4-tropic), or both (dual/mixed-tropic). Maraviroc is only effective against CCR5-tropic virus. Therefore, a tropism test is mandatory before starting therapy to ensure the patient's virus is susceptible. A is the prerequisite test for abacavir. C would be relevant for starting an INSTI. D is important for dose-adjusting many drugs, but it is not the specific, essential prerequisite for maraviroc's mechanism of action.

Question 16

A patient on an older ART regimen containing stavudine (d4T) develops painful peripheral neuropathy and pancreatitis. These dose-limiting toxicities are primarily attributed to the drug's off-target inhibition of which essential host cell enzyme?

  1. Cytochrome P450 3A4
  2. Cellular topoisomerase I
  3. Host cell RNA polymerase II
  4. Mitochondrial DNA polymerase gamma (correct answer)
Explanation: When you encounter questions about nucleoside reverse transcriptase inhibitors (NRTIs) like stavudine causing peripheral neuropathy and pancreatitis, think about mitochondrial toxicity. These symptoms are classic signs of mitochondrial dysfunction, which helps point you toward the mechanism. Stavudine's dose-limiting toxicities stem from its off-target inhibition of mitochondrial DNA polymerase gamma (pol γ). This enzyme is responsible for replicating mitochondrial DNA, which is essential for cellular energy production. When stavudine inhibits pol γ, it disrupts mitochondrial DNA synthesis, leading to mitochondrial dysfunction. Tissues with high energy demands—like peripheral nerves and pancreatic cells—are particularly vulnerable, explaining why patients develop painful neuropathy and pancreatitis. Answer choice A (Cytochrome P450 3A4) is incorrect because this hepatic enzyme metabolizes drugs but doesn't cause the specific mitochondrial toxicities described. Choice B (Cellular topoisomerase I) is wrong—this nuclear enzyme relieves DNA supercoiling during replication but isn't the target causing these particular side effects. Choice C (Host cell RNA polymerase II) is also incorrect since this enzyme transcribes mRNA in the nucleus and wouldn't produce mitochondrial dysfunction symptoms. The correct answer is D because mitochondrial DNA polymerase gamma inhibition directly explains both the mechanism and the clinical presentation. Study tip: Remember that older NRTIs (stavudine, didanosine, zidovudine) commonly cause mitochondrial toxicity through pol γ inhibition. When you see peripheral neuropathy, pancreatitis, or lactic acidosis with these drugs, think mitochondrial DNA polymerase gamma—it's a high-yield association for pharmacology exams.

Question 17

Ibalizumab is a monoclonal antibody used for multi-drug resistant HIV. Its mechanism of action is distinct from other entry inhibitors like maraviroc and enfuvirtide. Ibalizumab exerts its antiviral effect by:

  1. binding to domain 2 of the CD4 receptor on the host cell, which blocks viral entry after the initial attachment has occurred. (correct answer)
  2. binding to the CCR5 co-receptor on the T-cell, preventing its interaction with the viral gp120 protein.
  3. binding directly to the viral gp41 transmembrane protein, which physically blocks the conformational change required for membrane fusion.
  4. inhibiting the viral protease enzyme extracellularly, preventing the maturation of virions before they can infect new cells.
Explanation: When you encounter questions about HIV entry inhibitors, focus on understanding the sequential steps of viral entry: initial binding, conformational changes, co-receptor engagement, and membrane fusion. Each inhibitor targets a specific step in this cascade. Ibalizumab works through a unique mechanism among entry inhibitors. It binds to domain 2 of the CD4 receptor on host T-cells, creating a physical barrier that prevents the virus from completing entry even after it has already attached to the cell. This post-attachment inhibition is what makes it distinct from other entry inhibitors and particularly valuable against multi-drug resistant HIV strains. Let's examine why the other options are incorrect. Option B describes maraviroc's mechanism - it's a CCR5 antagonist that blocks the co-receptor, not ibalizumab's target. Option C describes enfuvirtide's mechanism, which binds to gp41 and prevents the conformational changes needed for membrane fusion. Option D is completely off-target since protease inhibitors work intracellularly after infection has occurred, and ibalizumab is an entry inhibitor, not a protease inhibitor. The correct answer is A because ibalizumab specifically targets domain 2 of CD4, creating a unique post-attachment block that distinguishes it from pre-attachment inhibitors. For pharmacology exams, remember that HIV drug mechanisms often follow the viral life cycle sequence. Entry inhibitors can work at different stages: pre-attachment (maraviroc), post-attachment (ibalizumab), or during fusion (enfuvirtide). Understanding where each drug acts in this sequence will help you tackle similar questions systematically.

Question 18

A patient's regimen is being switched from a boosted protease inhibitor (PI)-based regimen to an integrase inhibitor (INSTI)-based regimen. A potential advantage the patient is likely to experience with the new INSTI regimen is a significantly lower risk of developing:

  1. treatment-emergent lipoatrophy and potentially fatal lactic acidosis.
  2. neuropsychiatric side effects such as insomnia, depression, or vivid dreams.
  3. long-term metabolic complications such as hyperlipidemia and insulin resistance. (correct answer)
  4. a severe hypersensitivity reaction if they are positive for the HLA-B*5701 allele.
Explanation: The correct answer is C. Protease inhibitors as a class, particularly when boosted with ritonavir, are strongly associated with metabolic side effects, including hyperlipidemia, insulin resistance, and lipodystrophy. While newer PIs are better tolerated, the class effect remains a concern. INSTIs generally have a much more favorable metabolic profile, making this a common reason for switching. A is characteristic of older NRTIs (e.g., stavudine). B can be a concern with some INSTIs (e.g., dolutegravir) and was a hallmark of the NNRTI efavirenz. D is specific to the NRTI abacavir.

Question 19

The primary goal of modern antiretroviral therapy (ART) is to achieve and maintain a plasma HIV RNA level below the limit of detection. According to major public health findings, what is the most significant clinical and social consequence of a patient achieving and maintaining this state?

  1. Complete eradication of the latent HIV reservoir in resting memory CD4+ T-cells.
  2. Full restoration of all immune functions and inflammatory markers to pre-infection levels.
  3. The risk of transmitting HIV to sexual partners is reduced to effectively zero. (correct answer)
  4. Elimination of the elevated risk for non-AIDS comorbidities, such as cardiovascular disease.
Explanation: The correct answer is C. Large clinical trials have demonstrated that when a person with HIV achieves and maintains an undetectable viral load through ART, they do not sexually transmit the virus to others. This concept is known as 'Undetectable = Untransmittable' (U=U). It is a profound consequence of effective ART, with major implications for public health, prevention, and reducing stigma. A is incorrect; ART suppresses replication but does not eradicate the latent reservoir, which is why it is not a cure. B is incorrect; while immune function (CD4 count) improves dramatically, some immune dysregulation and inflammation may persist. D is incorrect; ART reduces the risk of non-AIDS comorbidities but does not eliminate it entirely.

Question 20

A patient's antiretroviral regimen includes darunavir co-administered with a low dose of ritonavir. The primary pharmacological purpose of including ritonavir in this regimen is to:

  1. provide additive antiretroviral activity by inhibiting a different isoform of the HIV protease enzyme.
  2. inhibit intestinal and hepatic CYP3A4, thereby increasing the bioavailability and prolonging the half-life of darunavir. (correct answer)
  3. prevent the development of ritonavir-specific resistance mutations that could confer cross-resistance to darunavir.
  4. enhance the mandatory intracellular phosphorylation of darunavir within CD4+ lymphocytes.
Explanation: The correct answer is B. Low-dose ritonavir is used as a pharmacokinetic enhancer, or 'booster.' Its primary role is to potently inhibit the cytochrome P450 3A4 (CYP3A4) enzyme in the gut and liver. This reduces the first-pass metabolism of other protease inhibitors like darunavir, leading to higher plasma concentrations ('boosting'), a longer half-life, and allowing for less frequent dosing. A is incorrect because at the low doses used for boosting, ritonavir's own antiretroviral activity is minimal. C is incorrect; the purpose is pharmacokinetic, not resistance prevention in this manner. D is incorrect because protease inhibitors are not pro-drugs and do not require intracellular phosphorylation to be active.